These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 11206477)

  • 41. Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design.
    Cai X; Whitfield T; Hixon MS; Grant Y; Koob GF; Janda KD
    J Med Chem; 2013 May; 56(9):3701-9. PubMed ID: 23627877
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A bait and switch hapten strategy generates catalytic antibodies for phosphodiester hydrolysis.
    Wentworth P; Liu Y; Wentworth AD; Fan P; Foley MJ; Janda KD
    Proc Natl Acad Sci U S A; 1998 May; 95(11):5971-5. PubMed ID: 9600901
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design and synthesis of chiral and racemic phosphonate-based haptens for the induction of aldolase catalytic antibodies.
    Mu YQ; Gibbs RA
    Bioorg Med Chem; 1997 Jul; 5(7):1327-37. PubMed ID: 9377093
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structural basis for antibody catalysis of a disfavored ring closure reaction.
    Gruber K; Zhou B; Houk KN; Lerner RA; Shevlin CG; Wilson IA
    Biochemistry; 1999 Jun; 38(22):7062-74. PubMed ID: 10353817
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Three-dimensional structure-activity relationship modeling of cocaine binding to two monoclonal antibodies by comparative molecular field analysis.
    Paula S; Tabet MR; Keenan SM; Welsh WJ; Ball WJ
    J Mol Biol; 2003 Jan; 325(3):515-30. PubMed ID: 12498800
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Strategies for the selection of catalytic antibodies against organophosphorus nerve agents.
    Smirnov I; Belogurov A; Friboulet A; Masson P; Gabibov A; Renard PY
    Chem Biol Interact; 2013 Mar; 203(1):196-201. PubMed ID: 23123255
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Generation of polyclonal catalytic antibodies against cocaine using transition state analogs of cocaine conjugated to diphtheria toxoid.
    Basmadjian GP; Singh S; Sastrodjojo B; Smith BT; Avor KS; Chang F; Mills SL; Seale TW
    Chem Pharm Bull (Tokyo); 1995 Nov; 43(11):1902-11. PubMed ID: 8575031
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence that the mechanism of antibody-catalysed hydrolysis of arylcarbamates can be determined by the structure of the immunogen used to elicit the catalytic antibody.
    Boucher G; Said B; Ostler EL; Resmini M; Brocklehurst K; Gallacher G
    Biochem J; 2007 Feb; 401(3):721-6. PubMed ID: 17020536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Probing the effects of hapten stability on cocaine vaccine immunogenicity.
    Cai X; Whitfield T; Moreno AY; Grant Y; Hixon MS; Koob GF; Janda KD
    Mol Pharm; 2013 Nov; 10(11):4176-84. PubMed ID: 23927436
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The scope of antibody catalysis.
    Jacobsen JR; Schultz PG
    Curr Opin Struct Biol; 1995 Dec; 5(6):818-24. PubMed ID: 8749371
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiple reactive immunization towards the hydrolysis of organophosphorus nerve agents: hapten design and synthesis.
    Huang H; Han WG; Noodleman L; Grynszpan F
    Bioorg Med Chem; 2001 Dec; 9(12):3185-95. PubMed ID: 11711294
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Catalytic antibody activity elicited by active immunisation. Evidence for natural variation involving preferential stabilization of the transition state.
    Gallacher G; Jackson CS; Searcey M; Goel R; Mellor GW; Smith CZ; Brocklehurst K
    Eur J Biochem; 1993 May; 214(1):197-207. PubMed ID: 8508792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A structural basis for transition-state stabilization in antibody-catalyzed hydrolysis: crystal structures of an abzyme at 1. 8 A resolution.
    Kristensen O; Vassylyev DG; Tanaka F; Morikawa K; Fujii I
    J Mol Biol; 1998 Aug; 281(3):501-11. PubMed ID: 9698565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Complete reaction cycle of a cocaine catalytic antibody at atomic resolution.
    Zhu X; Dickerson TJ; Rogers CJ; Kaufmann GF; Mee JM; McKenzie KM; Janda KD; Wilson IA
    Structure; 2006 Feb; 14(2):205-16. PubMed ID: 16472740
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis of five enantiomerically pure haptens designed for in vitro evolution of antibodies with peptidase activity.
    Wagner J; Lerner RA; Barbas CF
    Bioorg Med Chem; 1996 Jun; 4(6):901-16. PubMed ID: 8818241
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies.
    Ulrich HD; Schultz PG
    J Mol Biol; 1998 Jan; 275(1):95-111. PubMed ID: 9451442
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Critical analysis of antibody catalysis.
    Hilvert D
    Annu Rev Biochem; 2000; 69():751-93. PubMed ID: 10966475
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An improved rapid method for selecting monoclonal antibodies with high catalytic activities.
    Yuan YR; Yang BH; Ji YY
    J Protein Chem; 1997 Nov; 16(8):733-8. PubMed ID: 9365921
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Peripheral cocaine-blocking agents: new medications for cocaine dependence. An introduction to immunological and enzymatic approaches to treating cocaine dependence reported by Fox, Gorelick and Cohen in the immediately succeeding articles (see pages 153-174).
    Sparenborg S; Vocci F; Zukin S
    Drug Alcohol Depend; 1997 Dec; 48(3):149-51. PubMed ID: 9449012
    [No Abstract]   [Full Text] [Related]  

  • 60. Polyclonal antibody catalytic variability.
    Stephens DB; Thomas RE; Stanton JF; Iverson BL
    Biochem J; 1998 May; 332 ( Pt 1)(Pt 1):127-34. PubMed ID: 9576860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.